LOX and pancreatic ductal adenocarcinoma: For instance, Miller et al. demonstrated that combination of a LOX antibody with gemcitabine improved survival of a pancreatic ductal adenocarcinoma (PDAC) model via inhibiting key microenvironment-mediated pro-survival signals without any evidence of increased penetrance of gemcitabine into tumors upon LOX inhibition31 in contrast to the studies described above30,53.